ReviewFrontiers in oncology2018
Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum levels of trace elements in patients with prostate cancer: a systematic review and meta-analysis.Cancer causes & control : CCC · 2025Pooled it
- Revealing Prostate Calcification Heterogeneity through Their Elemental Distribution.Chemical & biomedical imaging · 2025Article
- Exploiting Oxidative Stress as Achilles' Heel: From Redox Homeostasis to Ferroptosis in Prostate Cancer.Antioxidants (Basel, Switzerland) · 2025Review
- Borax Triggers Ferroptosis by Modulating the TfR1/GPX4/ACSL4 Pathway in Prostate Cancer Cells with Differential Androgen Sensitivity.Biological trace element research · 2025Article
- Determination and assessing the role of serum calcium, vitamin D, ferritin, and uric acid levels on prostate cancer risk.The Canadian journal of urology · 2025Article
- Iron-Deficiency Anemia Associated With Prostate Cancer, and Ameliorated by Anti-androgen Therapy.Cureus · 2025Article
- Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer.Molecular cancer · 2025Article
- Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.Nature reviews. Urology · 2024Review
- Metabolic Adaptation and Cellular Stress Response As Targets for Cancer Therapy.The world journal of men's health · 2024Review
- Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database.BMC cancer · 2023Article
- Recent progress in the effect of magnetic iron oxide nanoparticles on cells and extracellular vesicles.Cell death discovery · 2023Review
- The Carotenoid Diatoxanthin Modulates Inflammatory and Angiogenesis Pathways In Vitro in Prostate Cancer Cells.Antioxidants (Basel, Switzerland) · 2023Article
- Research progress of the engagement of inorganic nanomaterials in cancer immunotherapy.Drug delivery · 2022Article
- Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer.Journal of nanobiotechnology · 2022Article
- High altitude exposure affects male reproductive parameters: could it also affect the prostate?†.Biology of reproduction · 2022Review
- Iron in Cancer Progression: Does BACH1 Promote Metastasis by Altering Iron Homeostasis?Sub-cellular biochemistry · 2022Article
- Knockdown of ferritin heavy chain (FTH) inhibits the migration of prostate cancer through reducing S100A4, S100A2, and S100P expression.Translational cancer research · 2020Article
- Substantia nigra echogenicity is associated with serum ferritin, gender and iron-related genes in Parkinson's disease.Scientific reports · 2020Article
- The Intrinsic Biological Identities of Iron Oxide Nanoparticles and Their Coatings: Unexplored Territory for Combinatorial Therapies.Nanomaterials (Basel, Switzerland) · 2020Review
- An Iron Metabolism-RelatedOncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing amount of research has recently strengthened the case for the existence of iron dysmetabolism in prostate cancer. It is characterized with a wide array of differential expression of iron-related proteins compared to normal cells. These proteins control iron entry, cellular iron distribution but also iron exit from prostate cells. Iron dysmetabolism is not an exclusive feature of prostate cancer cells, but it is observed in other cells of the tumor microenvironment. Disrupting the machinery that secures iron for prostate cancer cells can retard tumor growth and its invasive potential. This review unveils the current understanding of the ways that prostate cancer cells secure iron in the tumor milieu and how can we exploit this knowledge for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.